Sickle Cell Disease Treatment with Arginine Therapy trial (STArT)

← Back to all studies

Sickle Cell Disease Treatment with Arginine Therapy trial (STArT)

Health Condition: Hematology (Sickle Cell)
Health Impact Domain: Safety of care, Effectiveness of care, Patient experience, Decreased incidence/length of hospitalization

Summary

This is a pivotal phase 3 clinical trial using arginine as a novel treatment of pain in children with SCD. Pain in sickle cell disease (SCD) is the leading cause of hospitalizations and ED visits for children with SCD. Arginine has properties that may improve blood flow during these acute occlusion of blood vessels.

Key Publications

Related Media

-

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of the Emergency Medical Services for Children Data Center award totaling $3,200,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.